FDA Pediatric Guidance Designed For "Meaningful" Information, PhRMA Says
This article was originally published in The Tan Sheet
Executive Summary
FDA is implementing FDAMA's pediatric provisions in a "manner designed to yield meaningful labeling information" on the use of drugs in pediatric patients, PhRMA maintains in recent comments on a citizen petition filed by generic drug companies.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning